The implications for cancer treatment and management have led to recommendations to increase the proportion of CRC and endometrial tumours that are tested for MMR defects [11–14], with the UK National Institute of Health and Care Excellence (NICE) recommending MMR testing of all CRCs [15]. Here, MRC1 is linked to colorectal carcinoma.